Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10044645 | 0.88 | PIK3CA (0.42) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL10044695 | 0.87 | PIK3CA (0.43) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL10044804 | 0.84 | AADAT (0.39) | — | |
| SCHEMBL10044652 | 0.81 | GSK3B (0.45) | HPGD | |
| SCHEMBL10044801 | 0.79 | AADAT (0.40) | PIK3CACYP3A4PIK3CD | |
| SCHEMBL10044797 | 0.78 | FPR2 (0.43) | PIK3CAPIK3CDALDH1A1 | |
| SCHEMBL10044688 | 0.76 | AADAT (0.39) | — | |
| SCHEMBL10044669 | 0.75 | PIK3CA (0.49) | PIK3CACYP3A4PIK3CGDYRK1A | |
| SCHEMBL14070845 | 0.74 | PIK3CA (0.41) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB | |
| SCHEMBL10044671 | 0.74 | PIK3CA (0.41) | PIK3CACYP3A4PIK3CGPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-07 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2012-06-21 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157429-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PIK3CA 52/4885CYP3A4 4251/4885PIK3CG 88/4885 |
| US-20100160287-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PIK3CA 52/4885CYP3A4 4251/4885PIK3CG 88/4885 |
| US-20140221336-A1 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES | JAK2, JAK1, JAK3 | PIK3CA 52/4885CYP3A4 4251/4885PIK3CG 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.